Qelbree® (viloxazine extended-release capsules)

Please see full Prescribing Info, including Boxed Warning, at https://bit.ly/4lGkM5r. Qelbree is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in adult and pediatric patients 6 years and older. WARNING: SUICIDAL THOUGHTS AND BEHAVIORS. In clinical studies, higher rates of suicidal thoughts and behaviors were reported in patients with ADHD treated with Qelbree than in patients treated with placebo. Closely monitor all Qelbree-treated patients for clinical worsening and for emergence of suicidal thoughts and behaviors. Please see full Important Safety Information in Posts tab above. This page is for healthcare professionals in the US only. Qelbree® is a registered trademark of Supernus Pharmaceuticals, Inc. All other trademarks are the property of their respective owners. ©2024 Supernus Pharmaceuticals, Inc. All rights reserved. QBE.2024-0003 This information is intended for use in the United States and Puerto Rico only.